Stopping oral antiviral treatment to cure chronic hepatitis B, is it in sight?

[1]  J. Niu,et al.  Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients. , 2020, The Journal of infectious diseases.

[2]  Q. Ning,et al.  Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Wukui Cao,et al.  Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  Sheng-Nan Lu,et al.  Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy , 2019, Hepatology International.

[5]  H. Janssen,et al.  Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study) , 2019, Gut.

[6]  M. Manns,et al.  Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. , 2019, The lancet. Gastroenterology & hepatology.

[7]  Yasuhito Tanaka,et al.  Combining hepatitis B core‐related and surface antigens at end of nucleos(t)ide analogue treatment to predict off‐therapy relapse risk , 2018, Alimentary pharmacology & therapeutics.

[8]  Y. Liaw,et al.  Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B , 2018, Hepatology.

[9]  T. Berg,et al.  Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. , 2017, Journal of hepatology.

[10]  E. Cholongitas,et al.  Discontinuation of oral antivirals in chronic hepatitis B: A systematic review , 2016, Hepatology.

[11]  JSH Guidelines for the Management of Hepatitis B Virus Infection , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  D. Vassilopoulos,et al.  Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. , 2012, Gastroenterology.

[13]  Keat Hong Lee,et al.  Reimbursement policies in the Asia-Pacific for chronic hepatitis B , 2014, Hepatology International.